Health Care • Biotechnology: Commercial Physical & Biological Resarch
$267.33 ▼ -7.73
(-2.81%)
MKT CAP: $45.33B • VOL: 1.15M
52W L $155 52W H $285
IQV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $16.31B | $15.40B | $14.98B |
| YoY Revenue Growth % | +5.9% | +2.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $2.18B | $2.20B | $1.98B |
| Operating Margin % | 13.4% | 14.3% | 13.2% |
| Net Income (GAAP) | $1.36B | $1.37B | $1.36B |
| EBITDA (Normalized) | $2.77B | $2.76B | $2.52B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $2.65B | $2.72B | $2.15B |
| Capital Expenditures (CapEx) | $734.0M | $693.2M | $674.3M |
| Free Cash Flow (FCF) | $1.92B | $2.02B | $1.47B |
| FCF Margin % | 11.8% | 13.1% | 9.8% |
| Return on Invested Capital (ROIC %) | 9.4% | 10.1% | 10.4% |
| Cash & Short-Term Equivalents | $1.98B | $1.70B | — |
| Total Debt (Short + Long Term) | $13.88B | $12.84B | $5.83B |
| Total Stockholders' Equity | $6.50B | $6.07B | $11.97B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IQV.